PressAugust 23, 2022 Mydecine Innovations Group Announces Private Placement; Interim Changes to Management and Board of Directors
PressAugust 23, 2022 Awakn Life Sciences Signs Second Licensing Partnership Agreement and Expands Commercial Operations Into Canada
PressAugust 22, 2022 Lobe Sciences Announces Update on Corporate Slide Deck Highlighting its Psilocin Compounds and Development Plans
PressAugust 22, 2022 Core One Labs’ Akome Achieves Another Milestone in Development of its Psychedelic Drug Formulas and Announces Positive Results from Neuro-Pharmacokinetics Studies
PressAugust 22, 2022 PharmAla Biotech to supply Major Australian Research Institute with LaNeo™ MDMA for Phase 3 Clinical Trial
PressAugust 19, 2022 HAVN Life Announces the close of the first tranche of its previously announced Financing Commitment by Alpha Blue Ocean and Warrant Amendments and the Issuance of Shares for Debt
PressAugust 18, 2022 Reunion Neuroscience Inc. Commenced Trading on the Toronto Stock Exchange August 17, 2022
PressAugust 16, 2022 Filament Health Announces Second Quarter 2022 Financial Results and Operational Highlights
PressAugust 16, 2022 Awakn Life Sciences Expands Commercial Operations into the U.S. – First Licensing Partnership Agreement with Revitalist
PressAugust 16, 2022 Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health
PressAugust 15, 2022 atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital
